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Available online 21 July 2016AbstractSex steroids influence the maintenance and growth of muscles. Decline in androgens, estrogens and progesterone by aging leads to the loss of
muscular function and mass, sarcopenia. These steroid hormones can interact with different signaling pathways through their receptors. To date,
sex steroid hormone receptors and their exact roles are not completely defined in skeletal and smooth muscles. Although numerous studies
focused on the effects of sex steroid hormones on different types of cells, still many unexplained molecular mechanisms in both skeletal and
smooth muscle cells remain to be investigated. In this paper, many different molecular mechanisms that are activated or inhibited by sex steroids
and those that influence the growth, proliferation, and differentiation of skeletal and smooth muscle cells are reviewed. Also, the similarities of
cellular and molecular pathways of androgens, estrogens and progesterone in both skeletal and smooth muscle cells are highlighted. The
reviewed signaling pathways and participating molecules can be targeted in the future development of novel therapeutics.
© 2016 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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Muscles form 45 and 35 percent of lean body mass in men
and women, respectively. In the third decade of human life, a
slow and progressive decrease of muscle mass and function in
a large proportion of older individuals has been called sarco-
penia [1]. Sarcopenia accompanied by decreased mobility,
physical disability, slow gait, and loss of independence which
all lead to poor quality of life in older people. At the age of 65
years, nearly 5% of people and after 80 years approximately
50% of people may suffer sarcopenia [2e4]. Rapid aging of
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).with age 65 and older respectively included 9.1%, 11% and
13.1% of the Korean population can show the importance of
attention to sarcopenia [5]. Age-related sarcopenia included
skeletal muscle [6], smooth muscle [7] and cardiac muscle [8].
Although sarcopenia definition is evolving [9] but generally it
is characterized by age-related muscle wasting. Apart from the
aging, other factors such as autoimmune disorders, inflam-
matory disease, and endocrine dysfunction lead to sarcopenia
[10]. Myofiber atrophy, intramuscular fat accumulation, loss of
motor unit, and fibrosis are several sarcopenia pathologies
which are introduced as responsible for deficits of muscle
function and mass [11,12]. In addition, suppression of
anabolic signaling, abnormal function of mitochondria in
muscle cells, and apoptosis play role in pathogenesis of sar-
copenia [13,14].
Loss in the function and mass of muscular tissue can be
caused by gradual decrease of circulating concentration of
estrogens and androgens [15]. For instance, men who receivedlsevier B.V. This is an open access article under the CC BY-NC-ND license
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clines in upper body muscle strength and function [16]. On the
other hand, post-pubertal growth and sexual dimorphism of
muscles are influenced by sex steroid hormones including
estrogens and androgens [17]. Delineation of the current
knowledge on how sex steroid hormones signals interact with
controlling of the intracellular molecular pathways, may be
useful for management of sarcopenia. This article reviews
available information on the interaction between sex steroid
hormones and muscles with a focus on the pathophysiology of
sarcopenia from pre-clinical and clinical perspectives.
2. Sex steroid hormones effects on muscles
Systemic hormones and load bearing have important roles
in regeneration and hypertrophy after muscle injury [18].
Anti- and pro-inflammatory cytokines, growth factors and
sex steroid hormones are the major systemic hormones which
influence muscle tissue function and mass [19]. Role of sex
steroid hormones on skeletal muscles includes i) regulation
of muscle metabolic function, ii) increase of muscle strength,
iii) maintenance and growth of muscle mass [20], and iv)
promotion of muscle repair after injury [21]. Therefore, men
and women muscle health can be implicated by decline of
sex steroid hormones [22] including decrease in mass and
size of striated muscles [22]. Estrogens and androgens have
different effects on the function of muscle cells regarding the
sex, muscle cell types and/or muscle anatomical position
[15].
Androgenic steroids including testosterone and mechanical
loading increase skeletal muscle mass and growth in the
normal males [23e25] and females [26]. Decrease in muscle
size and strength is reported in the cancer patients [27,28],
individuals receiving androgen deprivation therapy such as
prostate cancer patients as well as women in post-menopausal
conditions [22] and men suffered hypogonadism [29]. In
addition, premenopausal women with increased age experi-
ence decreases in androgens [30]. Endogenous suppression of
testosterone in aged men and women accounts for sarcopenia,
muscle fat infiltration and decreased muscular quality in men
more than the women [11]. Low bioavailable testosterone
associated with worse frailty status in the aged men [31]. In
the men with androgen deficiency [25,32,33] and the castrated
animal models [34,35], it was reported that testosterone
replacement therapy increased the strength and mass of mus-
cle. Regarding to the effect of androgen and anatomical po-
sitions of skeletal muscle, muscles associated with copulation
are more responsiveness to androgen than the weight bearing
locomotive ones in male rat models [35]. Furthermore, in
androgen receptor knockout mice, the peripheral muscle mass
and size was not different with wild type mice but the weight
of levator ani was reduced in comparison with the wild type
mice [36].
Positive effects of estrogen replacement therapy including
increase of muscle contractile function and post-exercise
damage protection are shown in the ovariectomized rat
models [37e40]. In post-menopausal women conflictingfindings after estrogen replacement therapy on muscular
quality are demonstrated [41e43]. Regarding to the effect of
estrogen and locomotion function of skeletal muscle, in female
mice, higher weight bearing muscles have more responsive-
ness to estrogens [39]. Except skeletal muscles, the cardiac
muscle [44] and smooth muscles [45] are more affected by
estrogens. Furthermore, increase in body fat in males with
estrogen deficiency is reported [46].
A few studies evaluated the progesterone effects on skeletal
muscle function and growth. Progesterone receptor presence is
reported in skeletal muscle cells [47] and some functions of
this steroid hormone in skeletal muscle are evaluated. Skeletal
muscle contractile characteristics were not affected by the
fluctuations in progesterone levels throughout the menstrual
cycle [48]. Furthermore, treatment with progesterone has no
effect on the capacity of skeletal muscle to oxidize lipids.
However, by physiological concentrations' treatment of
ovariectomized rats with both estradiol and progesterone,
progesterone inhibited the lipolytic effect of estradiol, and this
was restored with pharmacological concentrations of estradiol
[49]. In addition, progestins may reduce proliferation of sat-
ellite cells in skeletal muscle of cow [50]. Although the
number of studies in comparison with the previous explained
sex steroid hormones are low but some mechanisms are
evaluated related to progesterone and skeletal muscle cell
proliferation. In contrast, in smooth muscle cells, progesterone
effects on cell proliferation, growth and function are more
investigated. Both medroxyprogesterone acetate and etono-
gestrel reduce proliferation and migration of vascular smooth
muscle cells [51].
3. Sex steroid hormone receptors' action in muscles
Presence and activity of androgen receptor, estrogen re-
ceptor-a and eb and progesterone receptor are shown in
different cell types of skeletal muscles (Table 1). Mesen-
chymal stem cells, satellite cells, myoblasts and myocytes
express androgen receptors [52e54]. Muscles are associated
with reproduction express more androgen receptors than the
weight bearing muscles and the receptors are more sensitive to
androgens [35]. Up-regulation of expression of androgen re-
ceptors in rodents and human muscle cells is done by both
increase in androgen concentration [21,35,55] and resistance
trainings [56e59]. On the other hand, in male mice with
knocked out androgen receptor but not in females, muscle
mass decreased [60]. In specific androgen receptor knockout
satellite cells in male mice [61] and myocyte-specific
androgen receptor knockout male mice [36], mass reduction
of highly androgen sensitive muscles has been reported
whereas other peripheral muscles were not affected by specific
androgen receptor delectation. Contrary to those findings, over
expression of androgen receptor in transgenic rats increased
muscle mass, hypertrophied myofibers, decreased adipocytes
and increased oxidative metabolism [62,63]. Furthermore,
androgen receptors expression is detected in different types of
smooth muscle tissues including vessels [64], penis [65], and
myometrium [66].
Table 1
Detected receptors of sex steroids on different cell types of skeletal muscle.
Cell types Androgen receptor Estrogen receptor-a Estrogen receptor-b Progesterone receptor References
Mesenchymal stem cells þ ND ND ND [53]
Satellite cells þ þ þ ND [54,258]
Myoblasts þ þ þ ND [52,258]
Myocytes þ þ þ þ [47,52,73,258,259]
Fibroblasts þ þ þ ND [53,258]
ND: there is no available data.
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trogen receptor-a and -b in male and females [67]. Expression
pattern of estrogen receptors differ between sexes [68].
However, deletion of estrogen receptor-b in female mice could
not affect the muscle mass, but estrogen receptor-a knockout
mice showed increase in muscle mass and decreased con-
tractile properties [39]. In comparison with wildtype in both
sexes, knocking out of estrogen receptor-b improved the
contractile properties and post damage recovery in male mice
but not in females [69]. In addition, expression of both types of
estrogen receptors in smooth muscle cells have regulatory role
in proliferation and differentiation of these cells [70,71].
Although the presence progesterone receptors is detected
[72] in skeletal muscles, their role is not as clear as the other
sex steroid hormone receptors. On the other hand, although the
presence of progesterone receptor in myoblast cells are re-
ported [73], more investigations concerning to progesterone is
necessary to confirm presence and absence of this type of sex
steroid hormone receptor in other type of skeletal muscle cells.
This despite the fact that numerous study clarified role of
progesterone receptors in proliferation of smooth muscle cells
of various tissues with inhibitory effects in vessels [74] and
stimulatory effects in myometrium [75].Table 2
Recognized physiological effects of sex steroids on signaling pathways, paracrine
Signaling
pathways/molecules
Skeletal muscle
Androgen Estrogen Progesteron
Akt/mTOR Stimulation [94];
inhibition [88]
Stimulation [103,106] ND
FoxO3 Inhibition [88,119];
no effect [120]
No effect [120];
stimulation [106]
No effect [1
MAPK1/3 (ERK1/2) Stimulation [135] No effect [103];
stimulation [139]
ND
Wnt Stimulation [149] ND ND
Notch Stimulation [152];
inhibition [149]
ND ND
NF-kB Inhibition [166,169] ND ND
TNF-a ND Inhibition [188] ND
Interleukins Inhibition [88] Stimulation [188];
no effect [263]
Inhibition [1
MRF (MyoD and
myogenin)
Inhibition [119];
no effect [266]
Stimulation [203];
Inhibition [202]
Stimulation
CDK Stimulation [154] ND ND
Myostatin/AcIIb/Activin Inhibition [224,267];
no effect [120]
No effect [120] No effect [1
ND: there is no available data, although aFoxO3 [121], bCRFs [201] and cmyostat
Akt, serine/threonine-specific protein kinase; CDK, cyclin-dependent kinase; ER
MAPK1/3, mitogen-activated protein kinase 1/3; MRF, myogenic regulating factor
Tumor necrosis factor.4. Sex steroid hormones and intracellular pathways in
muscle cells
The role of sex steroid hormones in age-related changes in
sarcopenia and alterations of intracellular signaling pathways
in muscles is not well understood. Revealing the role of an-
drogens and related receptors in increase of protein synthesis
and skeletal muscle mass, understanding the molecular
mechanisms that mediate these effects may help to develop
supportive or even preventive therapy for the individuals
suffering from sarcopenia. Muscle synthesis or degradation is
regulated by several signaling pathways positively or nega-
tively. Signaling pathways, paracrine mediators, and gene
targets in the skeletal and smooth muscles which are regulated
by androgens, estrogen and progesterone are summarized in
Table 2.4.1. IGF-I/Akt/mTOR pathwayOne of the pathways which is controlled by androgenic
signals and has critical role in survival and growth of muscles
via protein synthesis is the insulin growth factor-1 (IGF-I)/
protein kinase B (Akt)/mammalian target of rapamycinmediators, and gene targets in the skeletal and smooth muscles.
Smooth muscle
e Androgen Estrogen Progesterone
Stimulation [95] Stimulation [108,260] Inhibition [110,143]
20] NDa ND ND
Stimulation [137] stimulation [140,142] Stimulation [114,142,143]
ND Stimulation [157] Stimulation [157]
No effect [261] ND ND
Inhibition [170] Inhibition [171,262] Inhibition [175];
stimulation [143]
Inhibition [170] Inhibition [190] Inhibition [176,192]
92] Inhibition [186] No effect [264];
inhibition [265]
Inhibition [193];
no effect [175]
[50,120] NDb ND ND
Inhibition [212] Inhibition [217] Inhibition [112,143]
20] NDc Inhibition [227] Inhibition [227]
in [227] are detected in smooth muscles.
K1/2, extracellular-signal-regulated kinases 1/2; FoxO3, Forkhead box O3;
s; mTOR, mechanistic target of rapamycin; NF-kB, nuclear factor-kB; TNF-a,
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inflammation can impede activation of muscle mTOR
signaling [78]. Protein synthesis enhanced by phosphorylation
of 4E-BP1 and p70S6K which are subsequent of activated
mTOR by Akt [79]. Also, Akt can inhibit glycogen synthase
kinase-3 beta (GSK3b) which is the inhibitor of protein syn-
thesis [80]. On the other hand, two isoforms of IGF-I which
synthesized in muscle tissue, mechano growth factor (MGF or
IGF-IEc) and the IGF-I which is similar to the ones which is
synthesized by liver, have auto- and paracrine effects [81].
IGF-I is increased by mechanical loading and testosterone by
the activation of Akt and androgen receptors have critical role
in IGF-I synthesis in myocytes [82]. Reduction in intramus-
cular IGF-I synthesis and circulating IGF-I is associated with
deficiency of androgens in men [29,83] or castrated rodents
[84,85]. On the other hand, androgen replacement in castrated
rodents increased muscle performance without increase in
muscle fiber growth or activation of the Akt/mTOR pathway
[86]. Additionally, testosterone induced IGF-I/Akt pathway by
increasing expression of IGF-I mRNA and glycogen synthase
kinase 3b (GSK3b) phosphorylation in female rats [87].Skeletal muscle cell
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Fig. 1. Schematic diagram of (A) androgen and (B) estrogen effects on AKT/
mTOR and FoxO signaling in skeletal muscle cells. Abbreviations: Akt,
serine/threonine-specific protein kinase; AMPK, 50-adenosine
monophosphate-activated protein kinase FoxO, Forkhead box O; GSK3b,
glycogen synthase kinase 3b; IGF-I, insulin growth factor-I; MHC, myosin
heavy chain; mTOR, mechanistic target of rapamycin; T2, testosterone.Ambiguous findings are present on the effect of testosterone
supplementation or castration on Akt activation in the skeletal
muscles [85,86,88]. Differences in the type of muscles were
examined as well as dose of androgen, type and duration of
testosterone deficiency may exhibit the variability in the
experimental findings on sensitivity of androgens on IGF-I/
Akt/mTOR pathway in skeletal muscle.
The other pathway can occur independent of activation of
upstream Akt is the mammalian target of rapamycin complex
1 (mTORC1) which its activation regulates several cellular
process such as protein synthesis [89,90]. Testosterone
induced increases in protein synthesis can be blocked by
rapamycin, the mTORC1 inhibitor, in myotubes [91]
(Fig. 1A). The mTORC1 repressors includes proline-rich
Akt substrate-40 (PRAS40), mammalian lethal with SEC13
protein 8 (mLST8), and 5'-adenosine monophosphate-
activated protein kinase (AMPK) [92,93]. Synthesis of mus-
cle myofibrillar protein decreased by androgen withdrawal
through Akt/mTORC1 pathway and was independent of acti-
vation of AMPK and reversed by testosterone administration
[94]. Low dose of testosterone activate mTOR pathway in-
dependent of Akt; while, high dose testosterone activated Akt
pathway in skeletal muscle fibers [94]. In smooth muscles,
same evidences of stimulatory effect of androgen on Akt
pathway are reported [95,96].
Estradiol induces the Akt phosphorylation in myoblasts
(Fig. 1B) [97]. Decrease in muscle Akt phosphorylation which
is induced by estrogen deficiency in ovariectomized rats
caused decrease in muscle mass [98]. On the other hand,
expression of IGF-I receptor in skeletal muscle cells increased
in post-menopausal women after estrogen replacement while
expressions of miRNAs such as miR-182, miR-223 and miR-
142-3p decreased [99]. Considering the skeletal muscle
glucose metabolism, activation of AMPK was suppressed inSkeletal muscle cell
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Fig. 2. Schematic diagram of androgen effects on mitogen-activated protein
kinase (MAPK) signaling in skeletal muscle cells. Abbreviations: ERK1/2,
extracellular-signal-regulated kinases 1/2; MAPK1/3, mitogen-activated pro-
tein kinase 1/3; MEF2, myocyte enhancer factor-2; MRF4, myogenic regu-
lating factor 4; SWI/SNF, SWItch/sucrose non-fermentable.
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In addition, in skeletal muscles, Akt/mTOR pathway is
inhibited by AMPK activation [101,102]. Estradiol also in-
creases translocation of glucose transporter, Glut-4 to the
plasma membrane through Akt pathway and cause increase of
myogenin and myosin heavy chain (MHC) which are impor-
tant in morphological appearance of skeletal muscles
[103e105]. Estradiol administration in postmenopausal
women induced up-regulation of expression of mTOR genes
[106]. Furthermore, in smooth muscle cells, IGF-I-stimulated
phosphoinosotide-3-kinase (PI3K) pathway up-regulation is
inhibited by increase in AMPK activation [107]. Estrogen
induce smooth muscle acute response through the PI3-kinase/
Akt signaling axis [108]. In uterine smooth muscles, estradiol
up-regulates of the amount of p-mTOR in rat [109].
A limited number of investigations studying the effects of
progesterone on the skeletal muscle cells, to the best of our
knowledge, none evaluating this steroid effect on the IGF-I/
Akt/mTOR pathway in the skeletal muscle cells. On the
other hand, progesterone down-regulates key components of
the mTOR pathway in myometrium [110]. Also, progesterone
inhibits proliferation and migration of smooth muscle cells
[74,111,112] by induction of p27 up-regulation through the
progesterone/cSrc/AKT/ERK 2/p38-mediated signaling
pathway [113,114].4.2. FoxO familyAkt inhibits protein degradation by the phosphorylation of
transcription factors in forkhead box O (FoxO) family [115]
(Fig. 1A). FoxO1 and 3 activated in muscle atrophy condi-
tions in skeletal muscles [19,116]. Testosterone down-
regulates transcription of FoxO-related genes and expression
of FoxO in skeletal muscle to inhibit muscle catabolism
[85,88,117], while castration increased them [85]. In addition,
testosterone can prevent dexamethasone-induced atrophy of
skeletal muscle by blocking the expression of FoxO1 gene
[118]. Suppression of FoxO family by androgen resulted in
myogenin/ubiquitin ligase-mediated atrophy pathways and
preserve muscle mass [119]. In postmenopausal women
skeletal muscle, expression of FoxO3 mRNA is greater than
premenopausal [120]. However, testosterone replacement
therapy had no effects on the FoxO3 mRNA expression in
postmenopausal women [120]. This different finding in post-
menopausal women with previous investigations in rodent
may related to aging effect on the inhibitory effects of
androgen and its receptor with FoxO family and needs more
investigation. On the other hand, although FoxO3 is detected
in smooth muscle cells [121] but the effect of androgens on
this molecular pathway has not been investigated yet.
The effect of estradiol on the FoxO family in skeletal
muscle is controversial. However, it is shown that estradiol
treatment had no effect on mRNA expression of FoxO3 in
skeletal muscle [120], but it is also shown that estradiol
treatment of postmenopausal women caused up-regulation of
both FoxO3 and FoxO1 in the skeletal muscles (Fig. 1B)
[106]. On the other hand, although FoxO3 is detected insmooth muscle [121] but there is no information on the effects
of estrogens on the FoxO3.
Progesterone treatment had no effect on FOXO3 mRNA
expression in skeletal muscle of premenopausal and post-
menopausal women [120]. Although FoxO3 is detected in
smooth muscles [121], but there is no data on the effect of
progesterone on FoxO3.4.3. MAPK pathwayIn the intracellular signal pathway, mitogen-activated pro-
tein kinases (MAPK) regulate muscle growth through i)
SWItch/sucrose non-fermentable (SWI/SNF) complex
recruitment for activation of muscle cell differentiation pro-
moters [122], ii) by E47 E-box protein phosphorylation to
enhance transcriptional activity of MyoD and myocyte
enhancer factor-2 (MEF2)A, -C, and -D factors [104,123,124],
and iii) phosphorylation of myogenic regulating factor 4
(MRF4) to inhibit it to facilitate myogenesis [125,126]
(Fig. 2). Extracellular-signal-regulated kinases 1/2 (ERK1/2),
which are classical MAPK, have role in differentiation, divi-
sion, growth in skeletal muscle cells. Their activation is
enhanced by growth factors [127], exercises [128], diverse
stress stimuli [129], and hormones [130,131]. Chronic
inflammation induces p38 and ERK1/2 signaling which leads
to muscle wasting [132,133]. Steroid hormones increased
skeletal muscle cell calcium release from their reservoirs and
simultaneously activate MAPK pathways [134]. It is also
shown that testosterone could activate ERK1/2 pathway in
skeletal muscle [135]. In smooth muscle cells testosterone had
biphasic stimulatory and inhibitory effects in low and high
concentration, respectively [136]. It is also shown in the both
dose dependent effects of testosterone, stimulation or inhibi-
tion of MAPK pathway had role in regulation of smooth
muscle cell proliferation [137]. Therefore, more investigations
are necessary to clarify the MAPK pathway role in the
androgen deficient sarcopenia patients or androgen supple-
mentation in sarcopenia animal models.
The effects of estrogen on ERK/MAPK signaling in muscle
cell differentiation is controversial [131,138]. It is shown that
ERK1/2 does not have role in muscle differentiation by
estradiol [103]. In contrast, it is reported that ERK1/2 is
activated by estradiol in skeletal muscle cells under differen-
tiation conditions [139]. Estradiol induces the expression of
myogenin and MHC in skeletal muscle by phosphorylation
p38 [103]. Therefore, to clarify the role of MAPK pathway in
skeletal muscle differentiation further investigation can be
performed. On the other hand in smooth muscle, estradiol
inhibits proliferation and migration of the cells via reversing
phosphorylation of p42/44 and p38 MAPK and through
estradiol receptors [140,141]. In contrast to reduce myogenic
tone of smooth muscle in pregnant uterus, estradiol has a
direct chronic effect in the up-regulation of ERK1/2 expres-
sion [142].
No investigations evaluated the progesterone effects on the
MAPK pathway in the skeletal muscle cells. On the other
hand, progesterone increased ERK1/2 protein in smooth
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cells, progesterone inhibited cell proliferation by activating the
cSrc/Kras/Raf-1/AKT/ERK/p38/IkBa/NFkB pathway up-
regulates the expression of p21cip1 and p27kip1 through
increasing the level of p53 protein [114,143].4.4. Wnt and Notch signalingWnt signaling stimulates the formation and differentiation
of skeletal muscle in embryo [144,145]. Activation of Myf5
(for Wnt1), MyoD (in the case of Wnt7a), or receptor Fzd7 (by
Wnt7a) are the regenerative effects of Wnt signaling pathway
in skeletal muscles [146,147]. In addition, Wnt signaling
decrease the inhibitory effect of Notch signaling to increase
the differentiation of muscles via promoting the myogenic
progenitors [148]. Androgen increased Wnt signaling via up-
regulation of Numb in myoblasts [149]. Also, nandrolone,
an anabolic androgen, activated Wnt-dependent up-regulation
of Numb and resultant reduced Notch signaling during dif-
ferentiation of muscle progenitor cells [149]. Furthermore, it is
also shown that nandrolone diminished mdm2 levels to sta-
bilize Numb protein in myoblasts [150]. Also, up-regulation of
Numb by nandrolone in denervated muscle reduced Notch
signaling [151]. Although some studies showed that indirectly
and via the Wnt pathway androgens decreased the Notch
signaling, but testosterone in murine muscles increased
expression of Notch 1, Notch 2 and Delta 1 [152]. In addition,
in older man satellite cells, testosterone increased Notch
expression [153]. Furthermore, in aged skeletal muscle of
mice, testosterone induced expression of Notch 1 receptor
[154]. All these findings demonstrate the up-regulatory effect
of testosterone on Notch signaling and skeletal muscle cell
proliferation. Thus, the Wnt signaling and the Notch signaling
are the other pathways which is stimulated by androgens to
promote proliferation and then differentiation of skeletal
muscle cells. On the other hand, although Wnt signaling
pathway is described in smooth muscle cells [155] but the
effect of androgens on this molecular pathway has not been
investigated yet.
There is no information regarding the effects of estradiol on
Wnt and Notch signaling in skeletal muscle, but it is shown that
estradiol in combination with trenbolone acetate increase the
expression of WISP2 (Wnt-1 inducible signaling pathway pro-
tein 2) in sheep skeletal muscle [156]. In smooth muscle,
Estradiol administration induces secretion of WNT11 and
WNT16, WNT ligands, from mouse myometrial cells which
express estrogen receptor a [157]. In both smooth and skeletal
muscle, the effect of estradiol on notch signaling is not clarified.
Studies on the progesterone effects via Wnt and Notch
signaling in skeletal and smooth muscles are not available.
There is only a study in smooth muscle myometrial cells
which showed progesterone in combination with estrogen in-
duces WNT ligands secretion [157].
4.4.1. NF-kB pathway
Skeletal myogenesis inhibition is enhanced by nuclear
factor-kB (NF-kB) pathway activation [158]. The TNF-a andproteolysis-inducing factor (PIF) are the cytokines which
activate NF-kB to induce proteolysis and apoptosis in skeletal
muscles [159e163]. Stimulation of inflammatory pathways
which activate NF-kB in sarcopenia leads to acute or gradual
muscle wasting [164,165]. NF-kB induces skeletal muscle
atrophy by pro-inflammatory cytokines through downstream
signaling requiring RelA/p65 [164]. In a normal skeletal
muscle an upstream NF-kB pathway activating kinase, NF-
kBeinducing kinase (NIK), maintains at low basal levels
[166]. Stimulation of NF-kB noncanonical pathway leads to
cIAP1/2 degrades and ubiquitinates TRAF3. TRAF3 releases
and stabilizes NIK and causes NIK accumulation in cells
[167,168]. There is an association between aging and accu-
mulation of NIK in skeletal muscles in older men [166].
Activation of NF-kB pathway by increase of NIK levels leads
to catabolism of muscle proteins and sarcopenia progression.
Testosterone supplementation can decrease NIK content in
skeletal muscle of older men [166]. In addition, simultaneous
testosterone and protein supplementation suppressed p52 and
RelB expression in skeletal muscle of women [169]. In older
women, suppressive effect of androgen administration on NF-
kB pathway for prevention of women sarcopenia is not clar-
ified. In contrast to the describe catabolic role of NF-kB in
skeletal muscles, a canonical p50/RelA pathway and non-
canonical p52/RelB pathway in the other model of NF-kB
signaling in skeletal muscle suggests these pathway effects in
myogenesis [158]. On the other hand, same inhibitory effect of
androgens on smooth muscle degradation through suppression
of NF-kB is also reported. IkB-a degradation and the LPS-
induced NF-kB nuclear translocation were prevented by
testosterone in rat smooth muscle of prostate [170].
However, NF-kB pathway is described in skeletal muscle
cells [158] but there is no data on the effects of estrogens on
the NF-kB pathway in these cells. In contrast, in smooth
muscle cells, gene transfer of estrogen receptor-a and estradiol
treatment inhibited NF-kB activation and induced cell prolif-
eration in aged rat [171]. In the rat uterus, estradiol treatment
also inhibited NOS II induction, which its promoter region
contains NF-kB binding sites [172,173]. Thus it can be
postulated that in postmenopausal women, decrease in
expression of functional estrogen receptor-a number and/or
decrease in estradiol levels activate NF-kB, but experiments
will be needed to clarify this subject both in smooth and
skeletal muscles.
Such as the previous mentioned pathways, progesterone
effect on this pathway in skeletal muscle also is not investi-
gated. However, investigations on this subject in smooth
muscle cells are available. It is shown that myometrium beside
the infiltrated inflammatory cells is a major source of in-
flammatory cytokines [174]. Functional progesterone with-
drawal during parturition activates NF-kB in myometrium
through progesterone receptors [175]. Also, expression of
progesterone receptors is down-regulated by IL-1b and TNF-a
in myometrial smooth muscle cells [175,176]. Therefore, these
both mechanisms can activate NF-kB in smooth muscles by
decreasing the progesterone effect in myometrium. In contrast,
it is shown that in vascular smooth muscle cells progesterone
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complex in the nucleus and the binding of progesterone re-
ceptor onto the NFkB binding fragment of the p53 promoter
[143]. Therefore, in vascular smooth muscle cells activation of
NF-kB is involved in the progesterone-induced up-regulation
of p27 [143]. These controversies may be related to the cell
types or species which are evaluated in these studies and need
to be more investigated.
4.4.2. Interleukins and tumor necrosis factor
Proinflammatory cytokines including tumor necrosis factor
(TNF)-a, interleukin (IL)-1b, and IL-6 increase by androgen
deficiency in both experimental and clinical studies [177,178];
while, decrease after androgen replacement therapy [179].
Muscle mass and strength in elderly peoples inversely related
to interlukin-6 (IL-6) and tumor necrosis factor alpha (TNF-a)
concentrations [180]. Furthermore, protein breakdown of rat
skeletal muscle is increased by the administration of IL-6
[181] or TNF-a [182]. Production of IL-6 has been
increased by activation of p50/RelA [183]. In cancer cachexia,
gradual chronic increase of IL-6 and absence of increased
TNF-a in this catabolic diseases are reported [184]. It is also
shown that following exercise, IL-6 is up-regulated in skeletal
muscle [185]. Castration of mice induced increasing of IL-1a
and decreasing of interferon-g (IFNg) and simultaneously
levator ani muscle atrophy, however testosterone could prevent
these side effects by down-regulation of IL-1a and up-
regulation of IFNg expressions [88]. On the other hand,
although effect of TNF-a is described in skeletal muscle cells
but the effect of androgens on this cytokine has not been
clarified. In the smooth muscle, at subphysiological testos-
terone, levels TNF-a, IL-2, IL-6, IL-10, IL-12, and IL-13 were
elevated [186].
After muscle injury, TNF-a expression increased within 24 h
and the increase was higher in ovariectomized rats [187,188].
Estradiol reduced TNF-a expression during regeneration of
skeletal muscle via estrogen receptor-b but not estrogen re-
ceptor-a and also promote expression of IL-10 [188].
It is also shown that estrogen treatment of male subjects
before acute eccentric exercise decreased neutrophil infiltra-
tion in skeletal muscle [189]. In smooth muscle cells,
expression of cytokine-induced neutrophil chemoattractant-2b
is inhibited by treatment with selective agonist of estrogen
receptor-b and also TNF-a-treated smooth muscle cells
chemotactic activity was reduced [190].
Probable role of progesterone in regulation of these factors
in skeletal muscles are unclear. Although it is demonstrated
that megestrol acetate, a synthetic progestin, reduced both
skeletal muscle size and serum IL-6 [191,192]. In smooth
muscles this role is partially defined. Although, progesterone
receptor does not play a role in down-regulation of pro-
inflammatory gene networks induced by IL-1b [175], but IL-
1a is decreased by progesterone through decreasing the sta-
bility of IL-1a mRNA by stimulating the production of an
intracellular intermediate [193]. Therefore, it can be claimed
that in both skeletal and smooth muscles, progesterone inhibit
production of inflammatory cytokines.4.4.3. Myogenic regulating factors
Muscle development and growth is controlled by the
myogenic regulatory factors (MRFs) including myogenin,
MyoD1, Myf5, and Myf6 [194]. Myogenesis can be inhibited
by notch signaling through the repressing the MyoD [195], as
well as by biding directly to MEF-2C [196]. Androgens
repressed myogenin which regulates the myoblasts transition
from the proliferative state to the terminally differentiated
myocytes [119,197]. The androgen maintains proliferation of
myoblasts by delaying myotube formation [119]. In contrast
with these findings, it is shown that testosterone via
enhancement of androgen receptors may increase myogenin in
mouse myoblast cell line [198]. While, dihydrotestosterone
had no effects on expression of myogenin in human skeletal
muscle cells (SkMC) as well as in in-vivo conditions in or-
chiectomy and androgen receptor knockout mice and also in
other MRF including MyoD1, Myf5, and Myf [119]. On the
other hand, in in-vivo conditions myogenin repressed by
androgen/androgen receptor pathway [119]. Regarding, SkMC
may not be an appropriate model for in-vitro evaluation of
proliferation of myocytes, despite the fact that expression level
of androgen receptors in SkMC is similar to in-vivo muscle
cells [199]. Expression levels of myogenin decreased
concomitant with increase in age and testosterone level in
male mice [200]. The variation of in-vitro methods or even cell
lines may result difference findings and evaluation of other
kinds of in-vitro and in-vivo models will be necessary to
clarify the effects of androgens on MRF. Furthermore,
although MRF are detected in smooth muscle cells [201] but
the effect of androgens on this molecular pathway has not
been investigated yet.
The effects of estrogens on myogenic regulating factors are
controversies. For instance the overexpression of exogenous
ERa in the presence of E2 decreased the expressions of
myogenin [202]. While, knockdown of ERb reduced myoge-
nin level in the presence or absence of estradiol [202]. It is
shown that estradiol can induce expression of USP19 and with
the above mentioned mechanism can repress myotube for-
mation [202]. On the other hand, estradiol induced expression
of MyoD mRNA in males to the levels found in females [203].
Therefore, further studies may clarify the role of estrogens in
regulation of myogenic regulating factors in male and female
skeletal muscles. In the smooth muscles, although myogenic
regulating factors are detected [201] but the effect of estrogens
on them are not available.
MYOD1 expression is increased by progesterone which
resulted in satellite cell activation in postmenopausal women
skeletal muscle cells [120]. In addition, progesterone and
megestrol acetate increased myogenin mRNA expression 2.5
times in bovine satellite cells and C2C12 cultures [50]. In
smooth muscle cells no data is available related to the effect of
progesterone on myogenic regulating factors.4.5. Cyclin-dependent kinaseCyclin-dependent kinases (CDKs) are protein kinases
family and are involved in regulating the cell cycle, mRNA
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Increasing age is related to the induction of CDK inhibitors
through Notch pathway [204]. It is shown that p21, a CDK
inhibitor [205], interferes regeneration of satellite cells
[206e208]. p21 expression increase is observed in mice
concomitant with the increase of age [154]. Furthermore, this
age-associated increase in expression of p21 was reversed by
testosterone administration [154]. On the other hand, inhibi-
tion of c-jun NH2-terminal kinase (JNK) by testosterone could
cause apoptosis suppression of muscle cells and increasing of
muscle fiber growth [154]. Suppression of JNK and up-
regulation of p21 could induce muscle cell proliferation
[209,210]. In androgen receptor knockout mice, expression of
the Cdkn1c (p57Kip2), a cell cycle regulatory gene, increased
[60] which has role in decreasing myoblast proliferation and
increasing myoblast cell cycle exit and differentiation [211].
Therefore, in part via the androgen receptors/CDK pathway,
the proliferative effect of androgens in skeletal muscle may be
performed. On the other hand, in smooth muscles, testosterone
inhibited activity of CDK2 and CDK6 [212]. CDK2 activity
has role in transition of cells from G1 to S [213]. It is also
shown that testosterone can block CDK2 in smooth muscles
through activation of CDK inhibitors p21cip11 and p27kip1
[214e216].
However, no data was found that directly show the effect of
estrogens on cyclin-dependent kinase in skeletal muscle cells
but this phenomenon is defined to a certain extent. A metab-
olite of estradiol with no affinity for estrogen receptors, 2-
Methoxyestradiol, arrests proliferating smooth muscle cells
by inhibition of cyclin D1 and B1 expression and cdk1 and
cdk4 activity and up-regulation of the expression of the cdk
inhibitor p27 [217]. It is also shown that estradiol exert an
antiproliferative effect in smooth muscle cells through the
inhibition of the cyclin D1 promoter activity in transfected
with cDNA for estrogen receptor-a [218]. In contrast, in
uterine smooth muscle cells, estradiol-induced over-
proliferation was accompanied by and up-regulation of cyclin-
dependent kinases and cyclin D1, cyclin E1, CDK2, CDK4,
and CDK6 and down-regulation of cyclin-dependent kinases
inhibitors [219]. Therefore, the effect of estrogens on cyclin-
dependent kinase depends on the origin of smooth muscle
cells.
Based on our knowledge, role of progesterone in cyclin-
dependent kinase regulation in skeletal muscles is not
explained. However, in smooth muscle cells, cyclin-dependent
kinase system is inhibited by progesterone via increase of
cyclin-dependent kinase-inhibitors, p21cip1 and p27kip1
[112,143].4.6. MyostatinMyocytes produce myostatin or growth differentiation
factor 8 which has an inhibitory autocrine action on muscle
cell differentiation and growth [220]. By suppressing the
MyoD activity, myostatin induces double muscled phenotype
[221e223]. Myostatin mRNA expression was suppressed by
testosterone in adult skeletal muscle of castrated rats [224]. Itis shown that there is androgen response element (ARE) in the
myostatin promoter [225]. The myostatin Knockout mice
failed to produce myotubes which is related to silencing of
Actc1, Acta1, and MyoD [226]. In contrast in women, myo-
statin mRNA expression after testosterone administration was
not different in premenopausal and postmenopausal women
[120]. Therefore, to clarify the effect of testosterone on
expression of mysostatin in female skeletal muscles, further
investigations are necessary. Furthermore, although myostatin
is detected in smooth muscle cells of uterus [227] but the
effect of androgens on this protein in myometrial cells has not
been clarified.
Estradiol treatment had no effect on myostatin mRNA
expression in skeletal muscle of premenopausal and post-
menopausal women [120]. In contrast, in uterine smooth
muscle cells of ovariectomized rats, myostatin expression
increased estrogen treatment decreased myostatin expression
[227].
In skeletal muscle cells, progesterone treatment had no
effect on mRNA expression of myostatin in postmenopausal
women [120]. On the other hand, in smooth muscle cells of
myometrium of rat uterus, myostatin expression is weakly
decreased by progesterone [227].
5. Sex steroid hormones therapy for sarcopenia
It is remains unknown whether the several mechanisms
responsible for sarcopenia discussed above can be controlled
by a single therapeutic intervention which leads to rescue of
muscle function and mass in old age. Furthermore, for the
treatment or prevention of sarcopenia a FDA approved mo-
dalities is not still present. On the other hand, limited efficiency
of current pharmacologic interventions and lack of standard-
ized primary outcome of anti-sarcopenia drugs are some dif-
ficulties in developing therapeutic interventions [228]. By the
way, based on the mechanisms of the effects of sex steroid
hormones, androgens, estrogens and progestogens several
therapeutic agents for treatment of sarcopenia can be discussed.5.1. Androgens-related therapeuticsIn castrated aged mice, early indices of muscle regeneration
are improved by testosterone supplementation [229]. In men,
300 to 1000 ng/dl (10.4 to 34.7 nmol/L) testosterone in serum
is considered as normal and low concentrations is  300 ng/dl
(10.4 nmol/L) testosterone and frank hypogonadism will
be  250 ng/dl (8.7 nmol/L) testosterone [230]. Testosterone
supplementation with low or low-normal levels in men aged
older than 45 years increase muscle mass and strength
[231,232]. In adult man, testosterone therapy has no effect on
prostate, cardiovascular outcomes and even mortality, but its
adverse effect including decrease in high-density lipoprotein
cholesterol and increase in hemoglobin and hematocrit is re-
ported [233]. In addition, increased risk of cardiovascular
adverse events, edema and worsening of sleep apnea were
observed in older men who were administrated testosterone
gel [230,234]. Sarcopenic elderly men most frequently
148 Y.J. Kim et al. / Osteoporosis and Sarcopenia 2 (2016) 140e155administered by intramuscular injection of long-acting
testosterone esters such as testosterone enanthate or testos-
terone cypionate at a dose between 50 and 400 mg every 2e4
weeks [235]. Also, transdermal administration via patch or gel
(1%, once daily between 50 and 100 mg) preparations and
infrequently via oral administration are reported [230].
Dehydroepiandrosterone (DHEA) displays androgenic
signaling in muscle cells by binding androgen receptors.
Benefit of DHEA supplementation in muscle strength or body
composition in older men and women remains inconclusive
[236,237]. On the other hand, DHEA in combination with
exercise improved physical strength in frailer adults [179,238].
Nandrolone (19-nortestosterone) is an anabolic steroid which
through activation of Notch signaling reduces muscle atrophy
in sarcopenia rat model [151]. Furthermore, administration
oxandrolone in combination with progressive resistance
training improved body composition in elderly women [239].
In addition, non-steroidal selective androgen receptor modu-
lators (SARMs) represent therapeutics for the treatment of
sarcopenia. Different SARMs including GLPG0492 [240],
andarine [241], NEP28 [242], enobosarm [243e245], MK-
0773 [246], and LGD2941 [247] are showed to have benefi-
cial effects on improvement of muscle mass. Therefore,
further clinical trials are necessary to evaluate effects of sup-
plementation with testosterones, DHEA, nandrolone, oxan-
drolone, and SARMs on elderly sarcopenic patients.5.2. Estrogens-related therapeuticsA meta-analysis showed that hormone therapy of post-
menopausal women with estrogen approximately 5% increase
strength of muscle [248]. Furthermore, risks of stroke, coro-
nary heart disease, breast and skin cancer, and pulmonary
embolism increased in postmenopausal women after use of
combination of estrogen and progestin [249e251]. Therefore,
for preventing or treating of sarcopenia in postmenopausal
women estrogen therapy is not recommended.5.3. Progestogens-related therapeuticsStudy shows directly the therapeutic effect of progestogens
on sarcopenia is not available. In menopausal women, pro-
gesterone administration (100 mg/d by using a vaginal insert)
improved muscle protein synthesis [120]. In elderly persons,
progestin such as megestrol acetate increases weight gain
[252,253]. On the other hand, oral bioidentical progesterone is
safer and more efficient than synthetic progestins. Bioidentical
progesterone cardiovascular safety [252,254] even in combi-
nation with transdermal estradiol [255] and also lower risk of
breast cancer [256,257] is better than synthetic progestins.
6. Conclusions
Further studies are needed to clarify the exact effects of sex
steroid hormones on the different types of muscle cells and
their interaction with the molecular pathways controlling
processes of apoptosis, proliferation and differentiation; butthe current knowledge on these signaling pathways may help
develop new therapeutics targeting the specifically related
receptors on skeletal or muscle cells. As have been discussed,
management of sarcopenia and improvement of muscle mass
condition or control of this tissue wasting needs a wide range
of studies that cover basic to clinical investigations.
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